Roger Jeffs - 24 Jun 2021 Form 4 Insider Report for ALBIREO PHARMA, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 24 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jun 2021, 16:05:14 UTC
Prior SEC filing: 08 Jun 2021
Next SEC filing: 01 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Jason Duncan, Attorney-in-fact

Key filing fact

Roger Jeffs filed Form 4 for ALBIREO PHARMA, INC. on 28 Jun 2021.

Key facts

This page summarizes Roger Jeffs's Form 4 filing for ALBIREO PHARMA, INC..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jun 2021, 16:05.

Change

Previous filing in this sequence was filed on 08 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALBO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +8,000
Change %
Price: $0.000000
Shares after: 8,000
Date: 24 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $36.87
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option will vest and become exercisable in full on the earlier of (i) June 24, 2022 or (ii) the day prior to the issuer's 2022 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date.